Dan Cole serves as a General Partner of Spray Venture Partners, which he founded in 1996 and a Venture Partner of Oxford Bioscience which he joined in 2009. Dan brings twenty years of medical device operational experience and has served on the Boards of 23 med-tech companies. Prior to joining Spray, Dan served as Senior Vice President and Group President of Boston Scientific Corporation's vascular business, a $1.2 billion group including SCIMED (cardiology), Medi-tech (radiology), Meadox (vascular surgery), and EP Technologies (electrophysiology). He was also responsible for BSC's rapidly growing international operations. Dan was previously President and Chief Operating Officer of SCIMED Life Systems, a public company with revenues of $260 million in 1994 prior to the company's merger with Boston Scientific in 1995. He previously held a variety of executive and general management positions at Baxter Healthcare Divisions. He currently serves on the Board of Directors of superDimension, Pathway Medical, Tryton Medical, Direct Flow Medical, PneumRx, Conventus Orthopedics, and Thoratec Laboratories.